A panel of experts on chronic myeloid leukemia have a comprehensive discussion on patient-centered care and the important role of shared decision-making in the optimal treatment of patients with CML.
This program was made possible with support from Novartis Pharmaceuticals.
EP. 4: Starting CML Treatment: Collaborative Choices for Better Outcomes
August 7th 2024Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies that optimize communication when considering treatment options.
Zipalertinib Promising for Heavily Pretreated EGFR Exon 20-Mutated Lung Cancer
Amivantamab Plus Chemo Trends Toward Long-Term Benefit in Advanced NSCLC
Neoadjuvant TAR-200/Cetrelimab Combo Generates Responses in Muscle-Invasive Bladder Cancer
Adding Relatlimab to Nivolumab/Chemo Did Not Increase Toxicity
2 Commerce Drive
Cranbury, NJ 08512